中国血液净化

中国血液净化 ›› 2020, Vol. 19 ›› Issue (09): 577-580.doi: 10.3969/j.issn.1671-4091.2020.09.001

• 全民健康助力全面小康●贫血专题 •    下一篇

腹膜透析患者血红蛋白变异管理策略

王晓阳1,赵占正1   

  1. 1郑州大学第一附属医院肾脏内科
  • 收稿日期:2020-06-30 修回日期:2020-07-14 出版日期:2020-09-12 发布日期:2020-09-03
  • 通讯作者: 赵占正 zhanzhengzhao@zzu.edu.cn E-mail:16796158@qq.com

Management of hemoglobin variation in peritoneal dialysis patients

  1. 1Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
  • Received:2020-06-30 Revised:2020-07-14 Online:2020-09-12 Published:2020-09-03

PDF

919

摘要： 【摘要】贫血是腹膜透析(peritoneal dialysis,PD)患者常见的并发症，我国PD 患者贫血治疗的达标率仍较低，氧感知通路受损、铁缺乏、炎症、营养缺乏等因素导致的红细胞生成素(erythropoietin, EPO)生成不足和低反应是PD 患者贫血的主要原因。PD 患者贫血的治疗除了要使血红蛋白(hemoglobin, Hb)维持在靶目标范围内，减少Hb 变异也很重要。Hb 变异性是受多种因素影响的一种临床现象，目前发现的导致血红蛋白变异的原因包括药物相关的因素、患者相关因素及炎症、铁缺乏、感染等。在PD 患者的贫血治疗期间必须预见到发生Hb水平变异的可能，减少Hb 变异，从而改善PD 患者预后。

关键词: 腹膜透析, 贫血, 血红蛋白变异

Abstract: 【Abstract】Anemia is a common complication of peritoneal dialysis (PD) patients. The compliance rate of anemia treatment is still lower in China. The mechanisms of anemia in PD patients include the deficiency of erythropoietin (EPO) production and lower EPO response due to abnormal oxygen sensing pathway, iron deficiency, inflammation, malnutrition and many others. In addition to maintain hemoglobin within the target range, to reduce hemoglobin variation is also essential in the treatment of anemia in PD patients. Hemoglobin variation is a clinical phenomenon affected by many factors including drug related factors, patient related factors, inflammation, iron deficiency, infection and many others. Hemoglobin variation and its related management must be concerned during the treatment of anemia in PD patients to improve their prognosis.

Key words: Peritoneal dialysis, Anemia, Hemoglobin variation

中图分类号: